Latest Articles
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data Nasdaq
Published: Jan. 8, 2026, 7:14 p.m.
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating TipRanks
Published: Jan. 8, 2026, 7:11 p.m.
Finding Purpose in Pain: The Enduring Impact of Endometriosis Patient Courtney Craig - Endometriosis Foundation of America
Finding Purpose in Pain: The Enduring Impact of Endometriosis Patient Courtney Craig Endometriosis Foundation of America
Published: Jan. 8, 2026, 6:09 p.m.
Turning Grief Into Purpose Through Advocacy And Awareness - Endometriosis Foundation of America
Turning Grief Into Purpose Through Advocacy And Awareness Endometriosis Foundation of America
Published: Jan. 8, 2026, 6:05 p.m.
OhioHealth Gynecologist Says You Don’t Have to Live With Endometriosis Pain - OhioHealth Newsroom
OhioHealth Gynecologist Says You Don’t Have to Live With Endometriosis Pain OhioHealth Newsroom
Published: Jan. 8, 2026, 4:04 p.m.
'Endometriosis has ruined my life' - BBC
'Endometriosis has ruined my life' BBC
Published: Jan. 8, 2026, 3:47 p.m.
Vaginal and gut microbiome dysbiosis linked to endometriosis - Contemporary OB/GYN
Vaginal and gut microbiome dysbiosis linked to endometriosis Contemporary OB/GYN
Published: Jan. 8, 2026, 3:41 p.m.
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe Nasdaq
Published: Jan. 8, 2026, 1:42 p.m.
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Australia
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com Investing.com Australia
Published: Jan. 8, 2026, 1:10 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Published: Jan. 8, 2026, 1:01 p.m.
Link copied to clipboard!